Pedersen N C, Johnson L
Department of Medicine, School of Veterinary Medicine, University of California, Davis 95616.
J Am Vet Med Assoc. 1991 Nov 15;199(10):1453-5.
Three commercial FeLV vaccines, (A, B, and C) were purchased on the open market and administered to 8- to 20-week-old specific-pathogen-free kittens, according to manufacturers' instructions. A similar group of nonvaccinated kittens served as controls. All kittens were challenge-exposed oronasally with virulent FeLV 4 weeks after the final vaccination. Serum samples were monitored for FeLV-p27 antigenemia using an ELISA at 1- to 2-week intervals for at least 16 weeks after the last day of challenge exposure. Kittens that were either transiently (1 to 4 weeks) or never viremic during this period were counted as recovered, whereas kittens that became viremic and retained viremia for at least 10 weeks were counted as persistently viremic. The 3 vaccines were found to be 39% (vaccine C), 28% (vaccine B), and 17% (vaccine A) efficacious in preventing persistent viremia in immunized, compared with nonimmunized kittens.
在公开市场购买了三种市售猫白血病病毒（FeLV）疫苗（A、B和C），并按照制造商的说明给8至20周龄的无特定病原体小猫接种。一组未接种疫苗的类似小猫作为对照。在最后一次接种疫苗4周后，所有小猫经口鼻腔接种强毒力FeLV进行攻毒。在攻毒暴露最后一天后，至少16周内每隔1至2周使用酶联免疫吸附测定（ELISA）监测血清样本中的FeLV-p27抗原血症。在此期间短暂（1至4周）病毒血症或从未出现病毒血症的小猫被视为康复，而出现病毒血症并持续至少10周病毒血症的小猫被视为持续病毒血症。与未免疫的小猫相比，发现这三种疫苗在预防免疫小猫持续病毒血症方面的有效率分别为39%（疫苗C）、28%（疫苗B）和17%（疫苗A）。
